Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Alefacept MeSH Descriptor Data 2025


MeSH Heading
Alefacept
Tree Number(s)
D09.400.430.890.034.500
D12.776.124.486.485.114.619.393.131
D12.776.124.790.651.114.619.393.131
D12.776.377.715.548.114.619.393.131
D12.776.395.550.034.500
D12.776.543.550.158.500
D12.776.828.300.100
Unique ID
D000077944
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000077944
Scope Note
A recombinant human fusion protein of LFA-3 antigen and immunoglobulin IGG1 that binds to CD2 ANTIGENS on memory T-LYMPHOCYTES, preventing their activation and proliferation. It is used in the management of moderate to severe chronic plaque PSORIASIS.
Entry Term(s)
Amevive
LFA-3 IgG(1) Fusion Protein
LFA-3 IgG1 Fusion Protein
Pharm Action
Dermatologic Agents
Immunologic Factors
Registry Numbers
ELK3V90G6C
0
Related Numbers
222535-22-0
Public MeSH Note
2019; ALEFACEPT was indexed under RECOMBINANT FUSION PROTEINS 2000-2018
History Note
2019 (2000)
Date Established
2019/01/01
Date of Entry
2018/07/09
Revision Date
2023/03/16
Alefacept Preferred
Amevive Narrower
page delivered in 0.135s